Potential New Drug for Some Patients with Treatment-Resistant Lung Cancer
In a recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics there was investigational drug AZD9291, a third-generation EGFR inhibitor which illustrated promise in preclinical studies. It also offered trusted hope for patients with advanced lung cancers which might have become resistant to existing EGFR inhibitors.
It was seriously studied that potent mutations in the growth factor gene EGFR are actively present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). The cogent studies also suggested that most numbers of NSCLCs harboring these EGFR mutations, respectively called activating mutations, which expediently respond to the EGFR inhibitor drugs erlotinib and gefitinib. The persuasive study also replicates that most of such cancers, develop resistance to these drugs within about nine to 11 months. In addition lot of cases are due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the “resistance mutation.”
It is also believed that no approved therapies so far to treat lung cancer patients who cinch develop the second mutation in the EGFR that actively stops the currently available medicines from working. This marvel innovative breakthrough was result of series in molecules which could target both the activating and resistance mutant forms of EGFR. It targets more expediently than normal EGFR, leading to development of the new EGFR kinase inhibitor, AZD9291.
In conclusion the recent findings from preclinical studies have successfully translated to the clinic, where the potent drug has demonstrated tumor shrinkage in patients and professionally tolerated, with low rates of side effects. The positive response to treatment with AZD9291 in such a haste period of time was well appreciated and trailblazing achievement. This new cogent drug has the ability to offer best treatment options for patients in this setting.